Why is conspiracy suspended

CNS Pharmaceuticals (CNSP) is facing potential delisting from the NASDAQ Capital Market due to non-compliance with the exchange's minimum bid price requirement. In response to the notification, CNS Pharmaceuticals has scheduled a hearing with a NASDAQ Hearings Panel for November 5, 2024. The upcoming hearing has postponed any immediate suspension or delisting actions. The Panel's decision post-hearing will determine if the company will be granted an additional extension to comply with the listing requirements. As of now, there is no certainty that the Panel will allow for such an extension. 1. **Non-compliance with NASDAQ Listing Requirements**: CNSP is at risk of delisting due to its failure to maintain the minimum bid price of $1.00 per share as required by NASDAQ. 2. **Hearing and Panel Decision**: CNSP has scheduled a hearing with a NASDAQ Hearings Panel for November 5, 2024, to determine its future listing status. 3. **Company's Efforts to Comply**: CNSP is attempting to argue its case for continued listing, citing its market capitalization of $5.04 million and the company's financial struggles, which include quickly burning through cash and weak gross profit margins. 4. **Outlook and Uncertainty**: Despite CNSP's efforts, there is no certainty that the Panel will allow for an extension, leaving the company's NASDAQ compliance and future trading status in limbo. In summary, CNSP is suspended from NASDAQ due to non-compliance with the exchange's listing requirements, and its future listing status will depend on the outcome of the hearing and the Panel's decision.